Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) shares plunged 65.99 percent to close at $5.83 a share last Wednesday. The stock traded between $4.00 and $6.10 on volume 114.83 million shares traded. The company announced that “patient enrollment in all clinical studies of Iclusig is being paused”. Shares of Ariad Pharmaceuticals have fallen approximately 70.0 percent year-to-date.
Get more information on Ariad Pharmaceuticals free access to the in-depth equity report at:
Cancer Genetics Inc. (NASDAQ: CGIX) shares dropped 17.92 percent to close at $15.39 a share last Wednesday. The stock traded between $15.15 and $17.75 on volume of 291,133 shares traded. The company announced plans to sell $46 million in common stock. Shares of Cancer Genetics have gained approximately 70.0 percent year-to-date.
Get more information on Cancer Genetics and free access to the in-depth equity report at:
CytRx Corporation (NASDAQ: CYTR) shares declined 18.61 percent to close at $2.23 a share last Wednesday. The stock traded between $2.18 and $2.26 on volume of 4.81 million shares traded. The company announced the pricing of a public offering of 10.0 million shares of common stock at a price of $2.25 per share. Shares of CytRx have gained approximately 20.0 percent year-to-date.
Get more information on CytRx and free access to the in-depth equity report at:
Lpath, Inc. (NASDAQ: LPTN) shares declined 15.57 percent to close at $4.12 a share last Wednesday. The stock traded between $3.87 and $4.20 on volume of 370,048 shares traded. The company has received notice from Pfizer Inc. that Pfizer is currently seeking to divest certain ophthalmology R&D assets. Shares of Lpath have fallen approximately 18.0 percent year-to-date.
Get more information on Lpath and free access to the in-depth equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Five Star Equities
Leave a comment...